

Yusuke Tomita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7027889/publications.pdf>

Version: 2024-02-01

67
papers

1,971
citations

279798

23
h-index

265206

42
g-index

70
all docs

70
docs citations

70
times ranked

3280
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy. <i>Internal Medicine</i> , 2022, 61, 1731-1734.	0.7	3
2	Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis. <i>Allergology International</i> , 2022, 71, 259-261.	3.3	4
3	Clinical impact of cerebral infarction in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 863-870.	2.2	2
4	A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 607-616.	2.8	5
5	<i>Clostridium butyricum</i> therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. <i>Oncolmunology</i> , 2022, 11, .	4.6	30
6	Ageing-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	21
7	Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia. <i>Respiratory Investigation</i> , 2021, 59, 187-193.	1.8	32
8	Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 177-183.	4.1	5
9	Heterogeneous tumor-immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti-PD-L1 antibody therapy. <i>Thoracic Cancer</i> , 2021, 12, 397-401.	1.9	4
10	Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater. <i>International Journal of Clinical Oncology</i> , 2021, 26, 78-86.	2.2	3
11	Airway <i>Pseudomonas aeruginosa</i> density in mechanically ventilated patients: clinical impact and relation to therapeutic efficacy of antibiotics. <i>Critical Care</i> , 2021, 25, 59.	5.8	3
12	Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist. <i>Translational Lung Cancer Research</i> , 2021, 10, 2588-2602.	2.8	5
13	TGF β 2 Signaling Activated by Cancer-Associated Fibroblasts Determines the Histological Signature of Lung Adenocarcinoma. <i>Cancer Research</i> , 2021, 81, 4751-4765.	0.9	26
14	Successful Low-dose Alternate-day Treatment with Lorlatinib in an Elderly Patient with Anaplastic Lymphoma Kinase-positive Metastatic Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 336-341.	0.1	1
15	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	2.8	12
16	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory) Tj ETQq0 0 0 rgBT /Overbck 10 Tf 5		
17	A Case of Advanced Non-small Cell Lung Cancer with Visual Impairment due to Dural Metastasis. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 423-428.	0.1	1
18	Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database. <i>Translational Lung Cancer Research</i> , 2021, 10, 4250-4265.	2.8	11

#	ARTICLE	IF	CITATIONS
19	Predictive value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 681-690.	2.2	9
20	BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis. <i>Vaccine</i> , 2020, 38, 6352-6356.	3.8	34
21	Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 684-694.	2.7	79
22	Association of Probiotic <i>Clostridium butyricum</i> Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1236-1242.	3.4	115
23	Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9705.	4.1	12
24	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1099-1109.	10.7	59
25	Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. <i>Pathology International</i> , 2020, 70, 287-294.	1.3	15
26	Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment. <i>Internal Medicine</i> , 2020, 59, 1199-1202.	0.7	6
27	Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, e235-e237.	1.2	2
28	Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells. <i>Internal Medicine</i> , 2019, 58, 3261-3265.	0.7	9
29	Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course. <i>Oncology Letters</i> , 2019, 18, 3914-3924.	1.8	5
30	The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 140.	3.7	18
31	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. <i>Journal of Clinical Medicine</i> , 2019, 8, 762.	2.4	53
32	Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2019, 19, 72.	2.0	29
33	A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient. <i>Immunity, Inflammation and Disease</i> , 2019, 7, 3-6.	2.7	26
34	Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. <i>Journal of Dermatological Science</i> , 2019, 93, 33-40.	1.9	15
35	Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases. <i>Anticancer Research</i> , 2019, 39, 923-931.	1.1	6
36	Lung abscess following bronchoscopy due to multidrug-resistant <i>Capnocytophaga sputigena</i> adjacent to lung cancer with high PD-L1 expression. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 852-855.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors. <i>Methods in Molecular Biology</i> , 2018, 1709, 423-441.	0.9	106
38	Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients. <i>Anticancer Research</i> , 2018, 38, 6543-6550.	1.1	3
39	Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient. <i>European Journal of Immunology</i> , 2018, 48, 1764-1767.	2.9	29
40	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	1.9	40
41	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4633-4641.	7.0	68
42	Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood. <i>Leukemia and Lymphoma</i> , 2017, 58, 923-931.	1.3	14
43	Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. <i>Oncotarget</i> , 2017, 8, 10425-10436.	1.8	179
44	Effects of <i>UGT1A1</i> genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 461-473.	2.0	32
45	The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. <i>Oncolmmunology</i> , 2016, 5, e1219008.	4.6	58
46	<i>UGT1A1</i> genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 450-460.	2.0	19
47	Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 118, 590-597.	2.5	23
48	An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. <i>Oncolmmunology</i> , 2016, 5, e1123368.	4.6	18
49	Identification of glypican-3-derived long peptides activating both CD8 ⁺ and CD4 ⁺ T cells; prolonged overall survival in cancer patients with Th cell response. <i>Oncolmmunology</i> , 2016, 5, e1062209.	4.6	36
50	Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology. <i>PLoS ONE</i> , 2016, 11, e0152384.	2.5	2
51	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. <i>Oncotarget</i> , 2016, 7, 54137-54156.	1.8	27
52	Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. <i>Cancer Science</i> , 2015, 106, 505-511.	3.9	40
53	Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. <i>Oncology Letters</i> , 2015, 10, 1155-1158.	1.8	12
54	Emerging immunotherapies for bladder cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 191-200.	2.4	24

#	ARTICLE	IF	CITATIONS
55	Immunotherapies for bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 586-596.	1.8	17
56	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , 2015, 16, 177-186.	10.7	240
57	A phase I study of TRC105 anti-endothelin A (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 116, 546-555.	2.5	55
58	Elderly infection in the community due to ST5/SCCmecII methicillin-resistant <i>Staphylococcus aureus</i> (the New York/Japan clone) in Japan: Pantone "Valentine leukocidin-negative necrotizing pneumonia. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 335-339.	3.1	8
59	Identification of immunogenic LY6K long peptide encompassing both CD4 ⁺ and CD8 ⁺ T-cell epitopes and eliciting CD4 ⁺ and CD8 ⁺ T-cell immunity in patients with malignant disease. <i>Oncolmmunology</i> , 2014, 3, e28100.	4.6	17
60	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2014, 20, 5392-5402.	7.0	83
61	Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1. <i>Human Immunology</i> , 2013, 74, 1400-1408.	2.4	20
62	Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4 ⁺ and CD8 ⁺ T cells. <i>Oncolmmunology</i> , 2013, 2, e25801.	4.6	12
63	Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4 ⁺ and CD8 ⁺ T-cell Epitopes: KIF20A-Specific CD4 ⁺ T-cell Immunity in Patients with Malignant Tumor. <i>Clinical Cancer Research</i> , 2013, 19, 4508-4520.	7.0	53
64	Establishment of HLA-DR4 Transgenic Mice for the Identification of CD4 ⁺ T Cell Epitopes of Tumor-Associated Antigens. <i>PLoS ONE</i> , 2013, 8, e84908.	2.5	4
65	Development of an Ideal and Potent Cancer Immunotherapy Designed by Consideration of HLA Polymorphism. <i>Major Histocompatibility Complex</i> , 2013, 20, 45-56.	0.1	0
66	Peptides derived from human insulin-like growth factor I mRNA binding protein 3 can induce human leukocyte antigen A2-restricted cytotoxic T lymphocytes reactive to cancer cells. <i>Cancer Science</i> , 2011, 102, 71-78.	3.9	26
67	A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T lymphocytes reactive to tumor cells. <i>Cancer Science</i> , 2011, 102, 697-705.	3.9	34